Peptide vaccination intended to activate HLA class II-restricted CD4 T cells garnered the attention in relation with cancer therapy42–44, and several “enhancer” compounds for peptide loading onto HLA have been reported21, 33, 36, 41. The gene discussed is CD4; the disease is cancer.